Professor Sychev Dmitry Alekseevich – MD, Professor of the Russian Academy of Sciences, Corresponding Member of the Russian Academy of Sciences
2013 to the present: Head, Department of Clinical Pharmacology and Therapy; Rector, Russian Medical Academy of Continuing Medical Education (RMACME), Ministry of Health of Russia
2015 to 2019: Vice-Rector for Innovation and Development, RMACME, Ministry of Health ofRussia
2/1, Barrikadnaya St., Build. 1, Moscow125993; Dmitry.alex.sychev@gmail.com
He is the author of more than 700 printing works, including those in journals, indexed in international Q2-Q1-level databases. He is a coauthor of 8 study guides, 2 textbooks, a coeditor of the textbook “Clinical Pharmacology”, 10 educational programs, a coauthor and one of the science editors of “The National Guide to Clinical Pharmacology”, as well as a coauthor of “The National Guide to Medical Genetics”, the author of 3 scientific monographs: “Clinical Pharmacogenetics” (2007), “Drug Metabolism: the Scientific Basis of Personalized Medicine” (2008), and “Polypharmacy in Clinical Practice: Problems and Solutions” (2016, 2018), the practicum for medical students “The General Issues of Clinical Pharmacology” (2010, 2013). Russian Federation Government prize winner in science and technology (2008); N.P. Kravkov prize winner of the Russian Academy of Sciences for the best work in pharmacology and toxicology in2009. Atotal of 5 candidate and 2 doctoral dissertations have been defended under his supervision.
He is Deputy Chairman, Clinical Pharmacology Task Force (since 2019); President, Society of Pharmacogenetics, Pharmacokinetics, and Personalized Therapy; a member of the Board of the Moscow City Scientific Society of Therapists; editor-in-chief of the journal “Pharmacogenetics and Pharmacogenomics”, a member of the editorial boards of the Russian journals “Vestnik RAMS”, “Clinical Pharmacology and Therapy”, “Pharmacokinetics and Pharmacodynamics”, “Antibiotics and Chemotherapy”, “Creative Cardiology”, “Biomedicine”, “Molecular Medicine”, “Pharmacy of Kazakhstan”, “Public Health of the Far East", “Modern Rheumatology”; a member of the Expert Council on Therapeutic Sciences, Higher Attestation Commission of Russia (in 2014 to 2019), an expert of the Russian Academy of Sciences, the Russian Foundation for Basic Research (RFBR), and the Russian Science Foundation (RSF).
His research interests are the applied aspects of clinical and pharmacological technologies for personalized medicine (pharmacogenetic testing, pharmacokinetic monitoring) in diseases of the internal organs, mental diseases, drug interactions, and polypharmacy in clinical practice, the problems of prevention of adverse reactions, and information technologies in clinical pharmacology.
List of publications:
1. Sychev DA, Shuev GN, Chertovskih JV, et al. The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia. Pharmgenomics Pers Med. 2016 May 25;9:59-63.
2.Sychev DA, Rozhkov AV, Kazakov RE, Ananichuk AV. The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation. Drug Metab Pers Ther. 2016 Sep 1;31(3):173-8.
3. Bordovsky S, Sychev D, Ilina E. Frequency of Potentially Dangerous Drug Combination Prescription in Elderly Patients with Cardiovascular Diseases. Clin Ther. 2016 Oct 6;38(10S):e22.
4. Sychev DA, Zastrozhin MS, Smirnov VV, et al. The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction.Pharmgenomics Pers Med. 2016 Sep 14;9:89-95.
5. Sychev DA, Burashnikova IS, Kazakov RE. 1846G>A polymorphism of CYP2D6 gene and extrapyramidal side effects during antipsychotic therapy among Russians and Tatars: a pilot study. Drug Metab Pers Ther. 2016 Dec 1;31(4):205-212.
6. Sychev DA, Shuev GN, Suleymanov SS, et al. Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations. Pharmgenomics Pers Med. 2017 Mar 31;10:93-99.
7. Mirzaev KB, Zelenskaya EM, Barbarash OL, et al. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmgenomics Pers Med. 2017 Apr 12;10:107-114.
8. Sychev DA, Rozhkov AV, Ananichuk AV, Kazakov RE. Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients. Drug Metab Pers Ther. 2017 May 24;32(2):109-114.
9.Zastrozhin MS, Brodyansky VM, Skryabin VY, et al. Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. Pharmgenomics Pers Med. 2017 Jul 7;10:209-215.
10.Sychev DA, Zastrozhin MS, Miroshnichenko II, et al. Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. Drug Metab Pers Ther. 2017 Sep 26;32(3):129-136.
11.Mirzaev KB, Sychev DA, Ryzhikova KA, et al. Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. Genet Test Mol Biomarkers. 2017 Dec;21(12):747-753. doi: 10.1089/gtmb.2017.0036. Epub 2017 Oct 12.
12.Denisenko NP, Sychev DA, Sizova ZM, et al. Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. Pharmgenomics Pers Med. 2017 Sep 27;10:253-259.
13.Rytkin E, Mirzaev KB, Grishina EA, et al. Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients? Pharmgenomics Pers Med. 2017 Sep 18;10:243-245.
14. Zastrozhin MS, Grishina EA, Ryzhikova KA, et al. The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. Pharmgenomics Pers Med. 2017 Dec 28;11:1-5.
15. Sychev DA, Vardanyan A, Rozhkov A, et al. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genet Test Mol Biomarkers. 2018 Jan;22(1):51-54. 10.1089/gtmb.2017.0152
16. Tarasov D, Tovbin D, Malakhov D, et al. The Development of New Factor Xa Inhibitors Based on Amide Synthesis. Curr Drug Discov Technol. 2018;15(4):335-350. 10.2174/1570163815666180215114732
17. Kryukov AV, Sychev DA, Andreev DA, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018 Mar 22;11:43-49. 10.2147/PGPM.S157111
18. Ivashchenko DV, Rudik AV, Poloznikov AA, et al. Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. Drug Metab Pers Ther. 2018 Jun 27;33(2):65-73. 10.1515/dmpt-2017-0036
19. Fedorinov DS, Mirzaev KB, Ivashchenko DV, et al. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). Drug Metab Pers Ther. 2018 Jun 27;33(2):91-98. 10.1515/dmpt-2018-0004
20. Sychev DA, Ashraf GM, Svistunov AA, et al. The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Des Devel Ther. 2018 May 8;12:1147-1156. 10.2147/DDDT.S149069
21. Denisenko NP, Sychev DA, Sizova ZM, et al. CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. Pharmgenomics Pers Med. 2018 Jun 18;11:107-112. 10.2147/PGPM.S159708
22. Zastrozhin MS, Grishina EA, Denisenko NP, et al. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmgenomics Pers Med. 2018 Jun 29;11:113-119. doi: 10.2147/PGPM.S160763
23. Zastrozhin MS, SorokinAS, Agibalova TV, et al. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. Hum Psychopharmacol. 2018 Oct 25:e2677. doi: 10.1002/hup.2677.
24. Zastrozhin MS, Antonenko AP, Nesterenko EV, et al. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. Drug Metab Pers Ther. 2018 Dec 19;33(4):187-194 pii: /j/dmdi.ahead-of-print/dmpt-2018-0019/dmpt-2018-0019.xml. doi: 10.1515/dmpt-2018-0019
25. Fedorinov DS, Mirzaev KB, Mustafina VR, et al. Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA). Drug Metab Pers Ther. 2018 Dec 19;33(4):195-200 pii: /j/dmdi.ahead-of-print/dmpt-2018-0015/dmpt-2018-0015.xml. doi: 10.1515/dmpt-2018-0015.
26. Sychev D, Shikh N, Morozova T, et al. Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I-II hypertension. Pharmgenomics Pers Med. 2018 Sep 20;11:157-165. doi: 10.2147/PGPM.S158401.
27.Mirzaev KB, Rytkin E, Ryzhikova KA, et al. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metab Pers Ther. 2018 Sep 25;33(3):109-118. doi: 10.1515/dmpt-2018-0006.
28.Sychev DA, Levanov AN, Shelekhova TV, et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmgenomics Pers Med. 2018 Jul 25;11:127-137. doi: 10.2147/PGPM.S169277.
29.Chebotareva AD, Levin OS, Markov DD, et al. Is it personalized treatment of dementia based on the CYP2D6 gene polymorphism possible? Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(6. Vyp. 2):90-94.
30.Zastrozhin MS, SorokinAS, Agibalova TV, et al. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. Hum Psychopharmacol. 2018 Nov;33(6):e2677.
31. Sychev DA, Abdullaev SP, Mirzaev KB, et al. Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. Mol Biol Rep. 2019 Jun;46(3):2761-2769.
32. Mirzaev KB, Samsonova KI, Potapov PP, et al. Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel. Mol Biol Rep. 2019 May 17.
33. Zastrozhin M, Skryabin V, Smirnov V, et al. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Can J Physiol Pharmacol. 2019 May 17.
34. Sychev DA, Shprakh VV, Kitaeva EY, et al. Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(3. Vyp. 2):45-52.
35.Zastrozhin MS, Skryabin VY, Miroshkin SS, et al. Pharmacogenetics of alcohol addiction: current perspectives. The Application of Clinical Genetics. 2019;12:131-140
36. Mirzaev KB, Fedorinov DS, Ivashchenko DV, Sychev DA. ADME pharmacogenetics: future outlook for Russia. Pharmacogenomics. 2019 Jul;20(11):847-865.
37. Mirzaev KB, Osipova DV, Kitaeva EJ, et al. Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. Drug Metab Pers Ther. 2019 Sep 27.
38. Kozlov AV, Ramenskaya GV, Sychev DA, et al. An improved extraction protocol for therapeutic dabigatran monitoring using HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Oct 4;1130-1131:121808
39. Sosin D, Ivashchenko D, Sozaeva Z, Ket al. Cognitive impairment in patients with treatment resistant schizophrenia: Associations with DRD2, DRD3, HTR2A, BDNF and CYP2D6 genetic polymorphisms. Neurology, Psychiatry and Brain Research. 2019;33:48–55.
40. Dorofeeva MN, Shikh EV, Sizova ZM, et al. Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects. Pharmacogenomics and Personalized Medicine 2019;12:329–339
41. Ivashchenko DV, Buromskaya NI, Savchenko LM, et al. Global trigger tool in child psychiatry: A treatment safety evaluation in adolescents with an acute psychotic episode. Int J Risk Saf Med. 2019 Sep 27. doi: 10.3233/JRS-195030. [Epub ahead of print].
42. Sychev DA, Abdullaev SP, Mirzaev KB, et al. Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. Mol Biol Rep. 2019 Jun;46(3):2761-2769.
43. Mirzaev KB, Samsonova KI, Potapov PP, et al. Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel. Mol Biol Rep. 2019;46(4):4195–4199.
